| 1376 |
National Cancer Institute |
Html |
en |
Cervical Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of cervical cancer. |
| Obstet Gynecol | 0.632265 |
| Ib-IIa cervical cancer | 0.622159 |
| cervical carcinoma | 0.7714 |
| Invasive cervical cancer | 0.634596 |
| cervical lesion | 0.589978 |
| cell cervical cancer | 0.622655 |
| Radiat Oncol Biol | 0.629582 |
| cervical carcinoma patients | 0.625359 |
| uterine cervix | 0.691758 |
| stage IB | 0.622493 |
| oncology group study | 0.594527 |
| cervical cancer screening | 0.639667 |
| pelvic radiation therapy | 0.616405 |
| Natl Cancer Inst | 0.715673 |
| early-stage cervical carcinoma | 0.617419 |
| cervical cancer | 0.919863 |
| advanced cervical carcinoma | 0.650637 |
| human papillomavirus infection | 0.632755 |
| radical surgery | 0.591536 |
| Gynecologic Oncology Group | 0.647439 |
| Gynecol Oncol | 0.719059 |
| stage cervical cancer | 0.656488 |
| human papillomavirus | 0.762889 |
| radiation therapy | 0.621545 |
| et al. | 0.77758 |
|
| early-stage cervical cancer | 0.645908 |
| IB cervical carcinoma | 0.685888 |
| advanced cervical cancer | 0.71286 |
| cervical cancer patients | 0.639703 |
| PUBMED Abstract | 0.66552 |
| high-risk cervical cancer | 0.623567 |
| Recurrent cervical cancer | 0.622873 |
| primary cervical cancer | 0.62989 |
| abnormal cervical cancer | 0.630972 |
| cervical cancer risk | 0.6957 |
| Abstract | 0.771164 |
| Clin Oncol | 0.627188 |
| invasive cervical carcinoma | 0.622845 |
| forecasts cervical cancer | 0.63215 |
| Oncol Biol Phys | 0.631517 |
| Cervical Cancer Meta-Analysis | 0.620594 |
| cervical intraepithelial neoplasia | 0.750465 |
| I/II cervical cancer | 0.623038 |
| HPV infection | 0.611536 |
| squamous cervical carcinoma | 0.629261 |
| squamous intraepithelial lesions | 0.632419 |
| IIA cervical carcinomas | 0.590932 |
| cervical cytologic specimens | 0.615306 |
| Wright TC Jr | 0.598346 |
|
CLICK HERE |
| 1469 |
National Cancer Institute |
Html |
en |
Adult Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of adult central nervous system tumors. |
| type anaplastic astrocytomas | 0.549962 |
| 5-year analysis | 0.459034 |
| rapid immunohistochemical analysis | 0.458442 |
| mutations aids diagnosis | 0.4781 |
| adjuvant temozolomide | 0.53303 |
| BRAF genetic alterations | 0.471994 |
| pontine gliomas | 0.467631 |
| concurrent radiation therapy | 0.474706 |
| MGMT promoter methylation | 0.572789 |
| Radiation Therapy Oncology | 0.484458 |
| oligodendroglial tumors | 0.468432 |
| adult high-grade glioma | 0.464776 |
| Nervous System Tumors | 0.717497 |
| Astrocytic Tumors Treatment | 0.922097 |
| diffuse astrocytomas | 0.480334 |
| prognostic factor | 0.47815 |
| patients | 0.62456 |
| Primary Central Nervous | 0.835704 |
| Tumor Type section | 0.826321 |
| low-grade gliomas | 0.476475 |
| randomized trials | 0.48238 |
| anaplastic gliomas | 0.467716 |
| Treatment Option Overview | 0.469049 |
| standard systemic chemotherapy | 0.485413 |
|
| mutant tumors | 0.500547 |
| malignant gliomas | 0.567609 |
| radiation therapy | 0.833741 |
| standard chemotherapy agent | 0.48857 |
| Lancet Oncol | 0.46722 |
| glioblastoma patients | 0.504986 |
| Radiation Therapy section | 0.489765 |
| deep-seated tumors | 0.489355 |
| Glioblastomas treatment section | 0.511285 |
| diffuse gliomas | 0.494198 |
| CNS tumors | 0.489107 |
| strong prognostic factor | 0.47196 |
| primary malignant glioma | 0.474955 |
| DNA repair enzyme | 0.549791 |
| standard local treatment | 0.596897 |
| Low-grade tumors | 0.493795 |
| oral agent temozolomide | 0.522443 |
| pilocytic astrocytomas | 0.562223 |
| particular glioma subtypes | 0.489447 |
| newly diagnosed glioblastoma | 0.602836 |
| activating point mutation | 0.473461 |
| Tumors Treatment section | 0.972163 |
| mutant-specific IDH1 antibody | 0.464835 |
| potential diagnostic utility | 0.459778 |
|
CLICK HERE |
| 1516 |
National Cancer Institute |
Html |
en |
Non-Small Cell Lung Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of non-small cell lung cancer. |
| clinical trial | 0.362125 |
| treatment | 0.336369 |
| cancer treatment | 0.206436 |
| chest | 0.203247 |
| Lung Cancer Treatment | 0.202852 |
| clinical trials | 0.52727 |
| external radiation therapy | 0.324228 |
| cancer cells | 0.448727 |
| body | 0.207207 |
| non-small cell lung | 0.914469 |
|
| tyrosine kinase inhibitors | 0.262427 |
| clinical trial search | 0.225847 |
| cancer clinical trials | 0.238028 |
| cell lung cancer | 0.82241 |
| lymph nodes | 0.205659 |
| stage | 0.200928 |
| tumor | 0.257927 |
| radiation therapy | 0.542207 |
| internal radiation therapy | 0.232058 |
| information | 0.22515 |
|
CLICK HERE |
| 1549 |
National Cancer Institute |
Html |
en |
Childhood Brain and Spinal Cord Tumors Treatment Overview (PDQ®)–Patient Version |
Brain and spinal cord tumors may be benign (not cancer) or malignant (cancer). Both types cause signs or symptoms and need treatment. Get information about the many kinds of brain and spinal cord tumors, signs and symptoms, tests to diagnose, and treatment in this expert-reviewed summary. |
| PDQ Childhood Brain | 0.257478 |
| cancer treatment | 0.297382 |
| spinal column | 0.245566 |
| body | 0.252077 |
| PDQ cancer information | 0.277635 |
| spinal cord tumor | 0.378418 |
| clinical trials | 0.370146 |
| health care providers | 0.249776 |
| Pediatric Treatment Editorial | 0.244163 |
| cancer information summary | 0.261575 |
| clinical trial | 0.273191 |
| Nervous System Tumors | 0.243367 |
| High-grade spinal cord | 0.281934 |
| recurrent childhood brain | 0.283273 |
| newly diagnosed brain | 0.237604 |
| NCI PDQ cancer | 0.242529 |
| tests | 0.251387 |
| brain stem | 0.243824 |
| Metastatic tumors | 0.243822 |
| Treatment Editorial Board | 0.245992 |
| childhood cancer | 0.271461 |
| Cord Tumors Treatment | 0.28928 |
| General Information section | 0.242596 |
| treatment | 0.384234 |
| childhood spinal cord | 0.316653 |
|
| cancer cells | 0.347188 |
| standard treatment | 0.240256 |
| tumor risk group | 0.274387 |
| childhood brain | 0.596751 |
| spinal tap | 0.246398 |
| signs | 0.239529 |
| Benign brain tumors | 0.275877 |
| treatment clinical trials | 0.238797 |
| National Cancer Institute | 0.261551 |
| tumor cells | 0.240778 |
| Low-grade spinal cord | 0.282176 |
| effects cancer treatment | 0.24403 |
| new treatment | 0.262653 |
| types | 0.237657 |
| childhood cancer information | 0.249646 |
| childhood brain tumors | 0.325204 |
| PDQ summary | 0.248201 |
| tumor marker test | 0.242818 |
| Spinal cord nerves | 0.295114 |
| Malignant brain tumors | 0.275792 |
| cancer | 0.437578 |
| information | 0.284357 |
| spinal cord tumors | 0.945242 |
| brain stem controls | 0.239043 |
|
CLICK HERE |
| 1673 |
National Cancer Institute |
Html |
en |
Pediatric Supportive Care (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the unique issues that arise for children during their treatment for cancer, after the completion of treatment, and as adult survivors of cancer. |
| cancer treatment | 0.649866 |
| adult cancer survivors | 0.601623 |
| childhood cancers | 0.565975 |
| evidence | 0.583514 |
| newly diagnosed cancer | 0.565444 |
| Dev Behav Pediatr | 0.562444 |
| cancer treatment experience | 0.590476 |
| long-term cancer survivors | 0.591049 |
| childhood cancer survivors | 0.698108 |
| psychological distress | 0.685844 |
| depressive symptoms | 0.576681 |
| childhood brain cancer | 0.596569 |
| children | 0.767093 |
| young adult childhood | 0.567117 |
| healthy children | 0.56615 |
| health-related quality | 0.594398 |
| adolescents | 0.567273 |
| adult survivors | 0.665075 |
| cancer treatment process | 0.592904 |
| suicidal ideation | 0.593505 |
| childhood cancer | 0.981437 |
| cancer survivor study | 0.705202 |
| long-term survivors | 0.62768 |
| parents | 0.589868 |
|
| post-traumatic stress disorder | 0.567933 |
| cancer type | 0.563896 |
| young adult survivors | 0.629083 |
| Brain tumor survivors | 0.559844 |
| cancer experience | 0.564215 |
| Cancer Epidemiol Biomarkers | 0.56534 |
| PUBMED Abstract | 0.593091 |
| posttraumatic stress | 0.563988 |
| Pediatr Blood Cancer | 0.61246 |
| cancer report | 0.558535 |
| similar childhood cancers | 0.564039 |
| FDA Health Advisory | 0.559272 |
| pediatric cancer patients | 0.592812 |
| adult childhood cancer | 0.623021 |
| psychological distress symptoms. | 0.563319 |
| psychological adjustment | 0.574894 |
| Abstract | 0.609735 |
| adult’s cancer | 0.571622 |
| cancer survivorship | 0.563138 |
| childhood cancer survivor | 0.719437 |
| Zebrack BJ | 0.568169 |
| higher levels | 0.659906 |
| major depressive disorder | 0.587361 |
| post-traumatic stress | 0.585398 |
|
CLICK HERE |
| 2007 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores de células germinativas del sistema nervioso central infantil (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores de células germinativas del sistema nervioso central infantil. |
| craniospinal irradiation | 0.316255 |
| germ-cell tumors | 0.313995 |
| intracranial germinoma | 0.409628 |
| cns germ cell | 0.514596 |
| Tumor Study Group | 0.345102 |
| LCR lumbar | 0.316845 |
| germ cell tumours | 0.316685 |
| with chemotherapy | 0.342538 |
| Japanese Pediatric Brain | 0.336647 |
| Patients With Newly | 0.313535 |
| Calaminus G | 0.31314 |
| Radiat Oncol Biol | 0.37391 |
| Pediatric Brain Tumor | 0.404886 |
| Younger Patients With | 0.313094 |
| newly diagnosed cns | 0.31675 |
| nongerminomatous germ cell | 0.322146 |
| central nervous system | 0.442457 |
| with chemotherapy followed | 0.333351 |
| cell tumor study | 0.31798 |
| primary chemotherapy | 0.320021 |
| patients with | 0.448209 |
| radiation therapy | 0.332545 |
| with central nervous | 0.313181 |
| chemotherapy followed | 0.365679 |
| chemotherapy with | 0.323164 |
|
| carcinoma embrionario | 0.318514 |
| nervous system germ | 0.335764 |
| SIOP CNS GCT | 0.316308 |
| Primary intracranial germ | 0.315553 |
| Matsutani M | 0.312979 |
| Neuro Oncol | 0.319601 |
| Pediatr Blood Cancer | 0.338833 |
| system germ cell | 0.348752 |
| focal primary site | 0.31455 |
| Clin Oncol | 0.361515 |
| saco vitelino | 0.314073 |
| sistema nervioso central | 0.472998 |
| Oncol Biol Phys | 0.377556 |
| Brain Tumor Study | 0.347462 |
| Bifocal intracranial germinoma | 0.319163 |
| patients with localized | 0.323174 |
| germ cell tumors | 0.957656 |
| newly diagnosed | 0.329652 |
| treated with | 0.32552 |
| Brain Tumor Consortium | 0.321286 |
| Childs Nerv Syst | 0.319542 |
| Oncology Group | 0.314345 |
| tumor study | 0.348078 |
| primary site irradiation | 0.315366 |
|
CLICK HERE |
| 2109 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de esófago (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre los factores que pueden influir en el riesgo de cáncer de esófago y sobre la investigación dirigida a la prevención de esta enfermedad. |
| siguientes factores | 0.969759 |
| voluntarios sanos | 0.42115 |
| Physician Data Query | 0.489663 |
| Estados Unidos | 0.430297 |
| libre uso | 0.411941 |
| suficiente ejercicio | 0.429799 |
| prevención revisa | 0.420955 |
|
| PDQ Prevención | 0.433383 |
| carcinoma epidermoide | 0.463013 |
| National Cancer Institute | 0.420887 |
| siguientes riesgos | 0.416828 |
| siguientes sumarios | 0.467407 |
| Instituto Nacional | 0.441845 |
|
CLICK HERE |
| 3461 |
National Cancer Institute |
Html |
es |
Temas sobre terapias integrales, alternativas y complementarias (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos de información sobre las terapias integrales, alternativas y complementarias para personas con cáncer. |
| llamada lactobacillus acidophilus | 0.320398 |
| Sun’s Soup | 0.3376 |
| Flor Essence | 0.384105 |
| NCI Best Case | 0.324965 |
| Selected Vegetables | 0.574814 |
| sección suplementos | 0.322686 |
| vitamina d | 0.319364 |
| vitamina c | 0.341075 |
| sustancias quÃmicas llamadas | 0.324421 |
| Unidos Selected Vegetables | 0.324471 |
| Instituto Nacional | 0.442148 |
| sección pectina | 0.32118 |
| Salud Complementaria | 0.335148 |
| pacientes náuseas | 0.357085 |
| coenzima q10 | 0.48743 |
| PDQ Fatiga | 0.398645 |
| Health Interview Survey | 0.325066 |
| Estados Unidos | 0.550173 |
| sección complementos | 0.349035 |
| sección vitamina | 0.346665 |
| cardo mariano | 0.387654 |
| sección intervenciones | 0.319196 |
| punica granatum l | 0.321333 |
| sección intervención | 0.343132 |
| Centro Nacional | 0.320165 |
|
| sección ejercicio | 0.33994 |
| sección soja | 0.320395 |
| sección jengibre | 0.320032 |
| Sun's Soup | 0.379451 |
| sección té | 0.319269 |
| coenzima q10 ayuda | 0.329386 |
| hierba sonajero | 0.430937 |
| pacientes régimen gonzalez | 0.360587 |
| sección granada | 0.318618 |
| PDQ Temas | 0.374069 |
| salud náuseas | 0.319268 |
| pacientes linfedema | 0.359299 |
| San Juan | 0.409901 |
| sección licopeno | 0.323612 |
| sección tratamiento | 0.563476 |
| Physician Data Query | 0.356925 |
| sistema nervioso central | 0.321486 |
| enzimas pancreáticas | 0.337252 |
| cáncer renal | 0.379726 |
| sección terapia | 0.318859 |
| ¿El tratamiento | 0.326217 |
| sección selenio | 0.319463 |
| medicina complementaria | 0.95764 |
| terapia gerson | 0.366138 |
|
CLICK HERE |
| 15479 |
National Cancer Institute |
Html |
en |
Intramural Investigators Submitting Data |
Find general requirements for intramural investigators submitting genomic data. Different processes may exist based on operational differences in NCI intramural research programs. |
| dbGaP staff | 0.612313 |
| Institutional Certification | 0.866347 |
| review process | 0.634188 |
| accession number | 0.623142 |
| accuracy | 0.439647 |
| general requirements | 0.674142 |
| Institutional Review Board | 0.856814 |
| division | 0.480859 |
| Assignment | 0.440982 |
| NCI intramural research | 0.909946 |
| dbGaP Study Release | 0.812896 |
| DSPs | 0.462568 |
| initiation | 0.444589 |
| submission process | 0.630778 |
| Scientific Review | 0.648183 |
| contact | 0.441788 |
| human subjects | 0.63038 |
| studies | 0.475426 |
| required fields | 0.609497 |
| details | 0.440138 |
| expectations | 0.502409 |
| 3. | 0.437685 |
| genomic data | 0.866328 |
|
| DSP | 0.443274 |
| data submission formats | 0.913248 |
| dbGaP submission | 0.646264 |
| study submission information | 0.828375 |
| Basic Study Information | 0.823319 |
| center | 0.480797 |
| operational differences | 0.660458 |
| different processes | 0.658659 |
| steps | 0.441942 |
| QA/QC Data Submission | 0.891139 |
| submission portal | 0.629655 |
| data generation completion | 0.860975 |
| plans | 0.439922 |
| IRB | 0.460706 |
| Data Generation Completed | 0.868892 |
| quality assurance check | 0.803588 |
| GPA | 0.717674 |
| project proposal | 0.64122 |
| programs | 0.443042 |
| time | 0.4353 |
| send | 0.442857 |
| de-identified human specimens | 0.860465 |
|
CLICK HERE |
| 16380 |
National Cancer Institute |
Html |
es |
Toxicidad financiera del tratamiento del cáncer (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del riesgo de sufrir dificultades financieras durante el tratamiento del cáncer. |
| among patients with | 0.356148 |
| National Health Interview | 0.33762 |
| survivors identified through | 0.3506 |
| Guy GP Jr | 0.797953 |
| Targeted Cancer Therapies | 0.346578 |
| seguro médico | 0.502578 |
| Cancer Care Outcomes | 0.395905 |
| Medical Debt And | 0.338028 |
| Care Outcomes Research | 0.337105 |
| cancer care | 0.484521 |
| Adult Cancer Survivors | 0.410356 |
| Ekwueme DU | 0.389597 |
| estudio cancer care | 0.350705 |
| burden among | 0.343127 |
| Health Interview Survey | 0.341695 |
| Blough D | 0.351854 |
| Natl Cancer Inst | 0.34743 |
| cáncer versus | 0.347441 |
| Medicare Current Beneficiary | 0.347647 |
| cancer survivors | 0.793538 |
| Duke Cancer Institute | 0.343096 |
| with cancer | 0.974917 |
| patients with | 0.384813 |
| Medicare beneficiaries with | 0.362941 |
| Dowling EC | 0.336978 |
|
| Hardship Associated With | 0.350445 |
| United States | 0.354013 |
| financial hardship | 0.453927 |
| experiences with cancer | 0.407883 |
| Financial Hardship Associated | 0.350297 |
| Health Aff | 0.447932 |
| Care Cancer | 0.350503 |
| associated with cancer | 0.462553 |
| Debt And Bankruptcy | 0.341472 |
| Yabroff KR | 0.591176 |
| medical expenditure | 0.337994 |
| For Working-Age Cancer | 0.400083 |
| out-of-pocket health care | 0.387866 |
| Working-Age Cancer Survivors | 0.410894 |
| Clin Oncol | 0.748582 |
| breast cancer | 0.503347 |
| Rectal Cancer | 0.343774 |
| Non-elderly Cancer Survivors | 0.355648 |
| cáncer problemas | 0.341283 |
| financial toxicity | 0.423332 |
| patients receiving adjuvant | 0.339287 |
| MEPS Experiences with | 0.352286 |
| Current Beneficiary Survey | 0.336425 |
| expenditure burden | 0.396505 |
|
CLICK HERE |